| 应用 |
An EGFR-tyrosine kinase inhibitor |
| 产品介绍 |
Gefitinib (ZD1839)是一种EGFR抑制剂，作用于NR6wtEGFR和NR6W细胞中的Tyr1173，Tyr992，Tyr1173和Tyr992，IC50 分别为37 nM，37nM，26 nM和57 nM。 |
| 备注 |
Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. |
| 生化机理 |
Gefitinib is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and has been shown to increase phosphorylation of c-Jun NH2-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) in HaCaT cells. Studies suggest that gefitinib can enhance keratinocyte apoptosis via an EGFR-independent JNK-activation pathway. Research indicates that gefitinib can induce apoptosis in several cell lines including, HaCaT cells, KG-1, P39, and primary CD34+ myeloblasts. |
| 别名 |
ZD 1839;吉非替尼; N-(3-氯-4-氟苯基)-7-甲氧基-6-(3-吗啉-4-丙氧基)喹唑啉-4-胺;ZD 1839;Iressa;ZD-1839; ZD1839;N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine |
